FGF23 and Klotho: The new cornerstones of phosphate/calcium metabolism;FGF23 et Klotho: les nouveaux incontournables du métabolisme phosphocalcique

Archives de Pediatrie

Volumn 18, Issue 6, 2011, Pages 686-695

  Bacchetta, J ^a,b,c,d   Cochat, P ^a,b   Salusky, I B ^d  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c INSERM   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; OXYGENASE; PARATHYROID HORMONE; PHOSPHATE; SODIUM PHOSPHATE COTRANSPORTER 2A; SODIUM PHOSPHATE COTRANSPORTER 2C; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR;

APICAL MEMBRANE; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; ENZYME INHIBITION; HUMAN; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; OSTEOCYTE; PHOSPHATE METABOLISM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; CALCIUM; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; PHOSPHATES;

EID: 79957808224     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2011.03.004     Document Type: Short Survey

References (57)

1. ADHR Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348.
2. Razzaque M.S. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?. Am J Physiol Renal Physiol 2009, 296:F470-F476.
3. Fukumoto S., Yamashita T. FGF23 is a hormone-regulating phosphate metabolism - unique biological characteristics of FGF23. Bone 2007, 40:1190-1195.
4. Yamashita T. Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 2005, 9:313-318.
5. Salles J.P. Génétique des hypophosphatémies. Arch Pediatr 2006, 13:522-524.
6. Bacchetta J., Ranchin B., Dubourg L., et al. Vitamine D: un acteur majeur en santé ?. Arch Pediatr 2010, 17:1687-1695.
7. Amatschek S., Haller M., Oberbauer R. Renal phosphate handling in human - what can we learn from hereditary hypophosphataemias?. Eur J Clin Invest 2010, 40:552-560.
8. Karim Z., Gerard B., Bakouh N., et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 2008, 359:1128-1135.
9. Shenolikar S., Voltz J.W., Minkoff C.M., et al. Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting. Proc Natl Acad Sci U S A 2002, 99:11470-11475.
10. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
11. Krajisnik T., Bjorklund P., Marsell R., et al. Fibroblast growth factor 23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195:125-131.
12. Wesseling-Perry K. FGF23 in bone biology. Pediatr Nephrol 2009, 25:603-608.
13. Wang H., Yoshiko Y., Yamamoto R., et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008, 23:939-948.
14. Wesseling-Perry K., Pereira R.C., Wang H., et al. Relationship between plasma fibroblast growth factor 23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009, 94:511-517.
15. Quarles L.D. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003, 285:E1-E9.
16. Pereira R.C., Juppner H., Azucena-Serrano C.E., et al. Patterns of FGF23, DMP1 and MEPE expression in patients with chronic kidney disease. Bone 2009, 45:1161-1168.
17. Shimada T., Kakitani M., Yamazaki Y., et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
18. Hesse M., Frohlich L.F., Zeitz U., et al. Ablation of vitamin D signalling rescues bone, mineral, and glucose homeostasis in FGF23 deficient mice. Matrix Biol 2007, 26:75-84.
19. Stubbs J.R., Liu S., Tang W., et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007, 18:2116-2124.
20. Marsell R., Krajisnik T., Goransson H., et al. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor 23. Nephrol Dial Transplant 2008, 23:827-833.
21. Tsujikawa H., Kurotaki Y., Fujimori T., et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003, 17:2393-2403.
22. Kuro-o M., Klotho Pflugers Arch 2010, 459:333-343.
23. Kuro-o M. Klotho in chronic kidney disease - what's new?. Nephrol Dial Transplant 2009, 24:1705-1708.
24. Razzaque M.S. Klotho and Na+K+-ATPase activity: solving the calcium metabolism dilemma?. Nephrol Dial Transplant 2008, 23:459-461.
25. Liu S., Vierthaler L., Tang W., et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008, 19:2342-2350.
26. Chang Q., Hoefs S., van der Kemp A.W., et al. The beta-glucuronidase klotho hydrolyses and activates the TRPV5 channel. Science 2005, 310:490-493.
27. Fischer S.S., Kempe D.S., Leibrock C.B., et al. Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol 2010, 299:F1171-F1177.
28. Medici D., Razzaque M.S., Deluca S., et al. FGF23-Klotho signalling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 2008, 182:459-465.
29. Bacchetta J., Dubourg L., Harambat J., et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in paediatric chronic kidney disease. J Clin Endocrinol Metab 2010, 95:1741-1748.
30. Jonsson K.B., Zahradnik R., Larsson T., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003, 348:1656-1663.
31. Imel E.A., Peacock M., Pitukcheewanont P., et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006, 91:2055-2061.
32. Brown W.W., Juppner H., Langman C.B., et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 2009, 94:17-20.
33. Takaiwa M., Aya K., Miyai T., et al. Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period. Bone 2010, 47:256-262.
34. Carpenter T.O., Insogna K.L., Zhang J.H., et al. Circulating levels of soluble Klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment and relationship to parathyroid status. J Clin Endocrinol Metab 2010, 95:E352-E357.
35. Yamazaki Y., Imura A., Urakawa I., et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 2010, 398:513-518.
36. Prie D., Urena Torres P., et al. Latest findings in phosphate homeostasis. Kidney Int 2009, 75:882-889.
37. Gattineni J., Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2010, 25:591-601.
38. Lorenz-Depiereux B., Schnabel D., Tiosano D., et al. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010, 86:267-272.
39. Bacchetta J. Rachitisme hypophosphatémique. Progrès en pédiatrie, néphrologie pédiatrique 2011, Doin, sous presse. P. Cochat (Ed.).
40. Reyes-Mugica M., Arnsmeier S.L., Backeljauw P.F., et al. Phosphaturic mesenchymal tumor-induced rickets. Pediatr Dev Pathol 2000, 3:61-69.
41. Woo V.L., Landesberg R., Imel E.A., et al. Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108:925-992.
42. Benet-Pages A., Orlik P., Strom T.M., et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005, 14:385-390.
43. Topaz O., Indelman M., Chefetz I., et al. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet 2006, 79:759-764.
44. Danziger J. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant 2008, 23:2733-2737.
45. Juppner H., Wolf M., Salusky I.B. FGF23: more than a regulator of renal phosphate handling?. J Bone Miner Res 2010, 25:2091-2097.
46. Weber T.J., Liu S., Indridason O.S., et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003, 18:1227-1234.
47. Shimada T., Urakawa I., Isakova T., et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010, 95:578-585.
48. Galitzer H., Ben-Dov I.Z., Silver J., et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010, 77:211-218.
49. Lafage-Proust M.H. Does the downregulation of the FGF23 signalling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients?. Kidney Int 2010, 77:390-392.
50. Fliser D., Kollerits B., Neyer U., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007, 18:2600-2608.
51. Kazama J.J., Sato F., Omori K., et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005, 67:1120-1125.
52. Hsu H.J., Wu M.S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in haemodialysis patients. Am J Med Sci 2009, 337:116-122.
53. Nasrallah M.M., El-Shehaby A.R., Salem M.M., et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010, 25:2679-2685.
54. Gutierrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
55. Razzaque M.S. Does FGF23 toxicity influences the outcome of chronic kidney disease?. Nephrol Dial Transplant 2009, 24:4-7.
56. Oliveira R.B., Cancela A.L., Graciolli F.G., et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010, 5:286-291.
57. Aono Y., Yamazaki Y., Yasutake J., et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 2009, 24:1879-1888.